The development of post-transplantation antibodies against non-HLA autoantigens is
associated with rejection and decreased long-term graft survival. Although our knowledge of …

New biomarkers of early and late graft dysfunction are needed in renal transplant to improve
management of complications and prolong graft survival. A wide range of potential …

Autoantibodies to components of apoptotic cells, such as anti-perlecan antibodies,
contribute to rejection in organ transplant recipients. However, mechanisms of immunization …

The major medical advances in our knowledge of the human leukocyte antigen (HLA)
system have allowed us to uncover several gaps in our understanding of alloimmunity …

Antibodies that are specific to organ donor HLA have been involved in the majority of cases
of antibody-mediated rejection in solid organ transplant recipients. However, recent data …

Angiotensin II type 1 receptor (AT1R) antibody has been linked to poor allograft outcomes in
adult kidney transplantation. However, its clinical consequences in children are unknown …

Studies investigating the potential pathogenic effects of non-HLA antibodies (Ab) have
identified Ab against the angiotensin II type 1 receptor (AT 1 R-Ab) as a risk factor for …

In the renal allograft, transplant glomerulopathy represents a morphologic lesion and not a
specific diagnosis. The hallmark pathologic feature is glomerular basement membrane …

Introduction Autoantibody to angiotensin II type 1 receptor (AT1R-Ab) has been recognized
as a non-human leukocyte antigen (HLA) antibody relevant in transplantation. Endothelin …

Although solid organ transplant results have improved significantly in recent decades, a
pivotal cause of impaired long-term outcome is the development of antibody-mediated …